We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

124 hedge funds and large institutions have $3.15B invested in SpringWorks Therapeutics in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 56 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

457% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 7

250% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 16

76% more capital invested

Capital invested by funds: $1.79B → $3.15B (+$1.36B)

35% more funds holding

Funds holding: 92124 (+32)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

1.83% more ownership

Funds ownership: 87.13%88.96% (+1.8%)

Holders
124
Holders Change
+32
Holders Change %
+34.78%
% of All Funds
2.18%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
39
Increased
56
Reduced
16
Closed
7
Calls
Puts
Net Calls
Net Calls Change

SWTX Hedge Fund Activity: Q4 2020 in Review

124 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2020, worth a combined $3.15B — up 76% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SWTX positions and 7 closed out — a net gain of 32 holders — while 56 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $116M. The largest seller was BVF Inc, cutting an estimated $132M.

  • 124 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2020, up from 92 in Q3 2020.
  • Funds reported $3.15B of SpringWorks Therapeutics stock for Q4 2020, up 76% quarter-over-quarter.
  • 39 funds opened new SpringWorks Therapeutics positions in Q4 2020 and 7 closed out, a net change of +32 holders.
  • The largest SpringWorks Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $116M added.
  • The largest SpringWorks Therapeutics seller in Q4 2020 was BVF Inc, an estimated $132M sold.

Based on aggregated 13F filings for Q4 2020.